Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study

Recurrence of hepatocellular carcinoma (HCC) after transarterial chemoembolisation (TACE) is common due to neoangiogenesis. Cyclooxygenase-2 inhibitors and somatostatin analogues were reported to inhibit tumour angiogenesis. The pilot randomized controlled trial was aimed to prospectively evaluate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Huan, Wei, Bo, Chen, Shuang, Xie, Yong-Mei, Zhang, Ming-Guang, Zhang, Lin-Hao, Huang, Zhi-Yin, Tang, Cheng-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564648/
https://www.ncbi.nlm.nih.gov/pubmed/28430638
http://dx.doi.org/10.18632/oncotarget.15684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564648/
https://www.ncbi.nlm.nih.gov/pubmed/28430638
http://dx.doi.org/10.18632/oncotarget.15684

Ejemplares similares